Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SHR2285 in prevention of venous thromboembolism after total knee arthroplasty
NCT05203705Phase 2Terminated
- Sponsor
- Hengrui Therapeutics
- Start
- Mar 2022
- Primary completion
- Mar 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of shr2285 in venous thromboembolism (VTE) (5 arms), sponsored by Hengrui Therapeutics. Primary endpoints: Number of patients with confirmed composite endpoint at 12 days and Number of patients with composite bleeding at 12 days. Started Mar 2022; status: terminated.
02
Drugs
shr2285
03
Conditions
venous thromboembolism (VTE)
Beyond the preview
Go deeper on NCT05203705.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05203705.